{"entity":{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","aka":["PTCL","CTCL","Mycosis fungoides","Anaplastic large-cell lymphoma","Mature T-cell and NK-cell neoplasms","T-cell lymphoma","NK-cell lymphoma","Peripheral T-cell lymphoma, not otherwise specified","PTCL-NOS"],"tldr":"Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes.","summary":"PTCLs are a heterogeneous group: PTCL-NOS, nodal T-follicular-helper lymphomas (angioimmunoblastic), ALK-positive and ALK-negative anaplastic large-cell lymphoma (ALCL), adult T-cell leukaemia/lymphoma (HTLV-1), extranodal NK/T-cell lymphoma (EBV), enteropathy-associated and hepatosplenic T-cell lymphoma, and the cutaneous T-cell lymphomas (mycosis fungoides, Sézary syndrome). Except ALK-positive ALCL, five-year survival with CHOP is 30-40%.\n\nCHOP or CHOEP remains the backbone; brentuximab vedotin-CHP replaced CHOP for CD30-positive PTCL after ECHELON-2 (2018) and is the standard for ALCL. Autologous transplant consolidation in first remission is common practice without randomised proof. Relapsed disease is treated with pralatrexate (2009), the HDAC inhibitors romidepsin (2009, US PTCL indication withdrawn 2021) and belinostat (2014), brentuximab, or allogeneic transplant. NK/T-cell lymphoma uses asparaginase-based regimens (SMILE, P-GemOx) and radiotherapy; PD-1 blockade is active. Cutaneous T-cell lymphoma is managed by skin-directed therapy, then mogamulizumab (anti-CCR4, MAVORIC 2018), brentuximab (ALCANZA), bexarotene, extracorporeal photopheresis, and allogeneic transplant.\n\nOpen: TFH-lymphoma-directed epigenetic combinations (azacitidine-CHOP, ORACLE), CD30/CD7/CD5 CAR-T with fratricide engineering, and JAK/STAT inhibitors.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Peripheral_T-cell_lymphoma","links":[{"label":"NCCN Guidelines: T-Cell Lymphomas","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483"},{"label":"ECHELON-2 (Lancet 2019)","url":"https://doi.org/10.1016/S0140-6736(18)32984-2"},{"label":"NCI PDQ: mycosis fungoides","url":"https://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq"},{"label":"Lymphoma Action: helpline services","url":"https://lymphoma-action.org.uk/information-and-support/support-you/helpline-services"},{"label":"Lymphoma Action: questions to ask your medical team about lymphoma","url":"https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/questions-ask-your-medical-team-about-lymphoma"},{"label":"Lymphoma Action: follow-up after lymphoma treatment","url":"https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/follow-after-lymphoma-treatment"},{"label":"Lymphoma Action: infections, risk and prevention","url":"https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention"},{"label":"Lymphoma Action: neutropenia (low neutrophils)","url":"https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils"},{"label":"Lymphoma Action: cancer-related fatigue","url":"https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/cancer-related-fatigue"},{"label":"Lymphoma Action: lymphoma, work and you","url":"https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/day-day-living/lymphoma-work-and-you"},{"label":"Maggie's: support and information","url":"https://www.maggies.org/support-and-information/"},{"label":"Lymphoma Action: taking part in a clinical trial","url":"https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/clinical-trials-lymphoma-trialslink/taking-part-clinical"},{"label":"Lymphoma Action: autologous (your own) stem cell transplant","url":"https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/stem-cell-transplants/self-autologous-stem-cell"},{"label":"Macmillan: non-Hodgkin lymphoma","url":"https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/non-hodgkin-lymphoma"},{"label":"WHO Classification of Haematolymphoid Tumours, 5th edition: lymphoid neoplasms (Alaggio, Leukemia 2022)","url":"https://doi.org/10.1038/s41375-022-01620-2"},{"label":"International Consensus Classification of Mature Lymphoid Neoplasms (Campo, Blood 2022)","url":"https://doi.org/10.1182/blood.2022015851"}],"tags":["gap-fill","haematologic"],"related":["dlbcl","mantle-cell-lymphoma","follicular-lymphoma","rhoa-g17v","ig-tcr-clonality","lymphoma-roadmap","lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas","lymphoma-ev-the-drugs-that-cure-and-the-places-without-them"],"cancers":[],"sections":[],"technologies":["adc","monoclonal-antibody","epigenetic-drugs","autologous-stem-cell-transplant","allogeneic-hsct","car-t","palliative-care","psycho-oncology","peer-support-groups","survivorship-care-plan","fertility-preservation","financial-navigation","cbt-fatigue-distress","exercise-during-chemotherapy","multidisciplinary-tumour-board","oncology-nutrition","prehabilitation","clonality-testing","cgp","histopathology-ihc","flow-cytometry-mrd"],"targets":["cd30","ccr4","alk","pd1","cd52","cd38","stat3","stat5","jak1","jak3","rhoa","tet2","dnmt3a","vav1","irf4","plcg1","card11","fyn"],"drugs":["brentuximab-vedotin","pralatrexate","romidepsin","belinostat","mogamulizumab","azacitidine","crizotinib","pembrolizumab","doxorubicin","cyclophosphamide","vincristine","asparaginase","alemtuzumab","interferon-alfa"],"companies":["pfizer","takeda","bms","bioinvent-international","haihe-biopharma","immuneoncia-therapeutics"],"institutions":[],"pathways":["jak-stat","oncogenic-viruses","epigenetic-reprogramming","inflammation-nfkb"],"terms":["lugano-classification","histologic-transformation","lymphoma-tx-regimen-alphabet","lymphoma-tx-transplant-role","lymphoma-tx-pjp-and-infection-prophylaxis","lymphoma-tx-radiotherapy","lymphoma-tx-failed-and-negative","lymphoma-tx-uk-access","plasma-ebv-dna","cancer-related-fatigue","late-effects","febrile-neutropenia","neutropenia","financial-toxicity","central-venous-access","hypogammaglobulinaemia","performance-status","quality-of-life","lymphoma-decision-trial","lymphoma-decision-fertility-timing","lymphoma-living-fatigue","lymphoma-living-scanxiety-and-surveillance","lymphoma-living-returning-to-work","lymphoma-bio-htlv1","lymphoma-bio-lineage-antigen-cost","lymphoma-bio-ebv-latency","lymphoma-pit-score","lymphoma-htlv-1","lymphoma-classification-2022","lymphoma-b-versus-t-cell","lymphoma-indolent-versus-aggressive"],"trials":["nct06561048","nct06776952","nct06072131","nct04668690","alcanza","echelon-2","jcog9801","smile-enktl"],"people":[],"bottlenecks":[],"keyPapers":["paper-horwitz-lancet"],"journals":[],"dependsOn":[],"notes":["Living with a peripheral T-cell lymphoma, where a trial is more often the right first question: This is orientation from public patient pages, guidelines and the trials themselves, not advice for your case: your own team's instructions and the 24-hour number they gave you come first, and no figure here is a prediction about you. The decision records, the question sets, the first 60 days checklist and the red cards on this page were written from the NHS, Lymphoma Action, Macmillan and Cancer Research UK patient pages, from NICE NG52, NG47, CG151 and NG234, from the NHS Breast Screening Programme protocols and the Green Book, and from the trial reports named beside each figure, all read on 1 October 2026.","Taxonomy. This page is used as the hub for the mature T-cell and NK-cell lymphomas, which is wider than its name. WHO-HAEM5 reserves \"peripheral T-cell lymphoma, not otherwise specified\" for a single entity within the family it calls other peripheral T-cell lymphomas, and files the anaplastic large cell lymphomas, the nodal T-follicular helper cell lymphomas, the EBV-positive NK/T-cell lymphomas, the intestinal T-cell lymphomas and the primary cutaneous T-cell lymphomas as separate families. The corpus keeps this page as the entry point because it is where a reader arrives, and the entities now have pages of their own, listed above."],"group":"haematologic","burden":"Peripheral T-cell lymphomas make up about 10-15% of non-Hodgkin lymphomas in the West, more in Asia; there are over 30 WHO subtypes, most individually rare.","subtypes":["PTCL, not otherwise specified","Nodal TFH lymphoma (angioimmunoblastic type)","ALK-positive ALCL","ALK-negative ALCL (DUSP22, TP63 subsets)","Adult T-cell leukaemia/lymphoma (HTLV-1)","Extranodal NK/T-cell lymphoma (EBV)","Mycosis fungoides / Sézary syndrome (CTCL)","Enteropathy-associated and hepatosplenic T-cell lymphoma"],"biomarkers":["CD30 expression (brentuximab)","ALK rearrangement","TFH markers (PD-1, CXCL13, ICOS) and RHOA G17V / TET2 / IDH2 R172","EBV DNA (NK/T-cell)","HTLV-1 serology","CCR4 (mogamulizumab)","TCR clonality"],"standardOfCare":[{"setting":"First line, CD30+ PTCL / ALCL","approach":"Brentuximab vedotin + CHP ×6 (ECHELON-2, OS benefit) ± consolidative autologous transplant.","refs":["brentuximab-vedotin","autologous-stem-cell-transplant"],"guideline":{"nccn":"Category 1 (ALCL)","esmoMcbs":"4","version":"NCCN Guidelines: T-Cell Lymphomas","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483"}},{"setting":"First line, other nodal PTCL","approach":"CHOP or CHOEP (≤60 years) ×6, autologous transplant consolidation in responders; clinical trial preferred.","refs":["doxorubicin","cyclophosphamide","vincristine","autologous-stem-cell-transplant"],"guideline":{"nccn":"Category 2A","version":"NCCN Guidelines: T-Cell Lymphomas"}},{"setting":"Relapsed/refractory PTCL","approach":"Pralatrexate, belinostat, romidepsin (ex-US), brentuximab (CD30+), gemcitabine-based regimens, allogeneic HSCT for fit responders.","refs":["pralatrexate","belinostat","romidepsin","brentuximab-vedotin","allogeneic-hsct"],"guideline":{"nccn":"Category 2A","version":"NCCN Guidelines: T-Cell Lymphomas"}},{"setting":"Mycosis fungoides / Sézary","approach":"Skin-directed therapy (topical steroids, phototherapy, radiotherapy, total-skin electron beam), then mogamulizumab (MAVORIC), brentuximab (ALCANZA, CD30+), bexarotene, interferon, photopheresis; allogeneic HSCT for advanced disease.","refs":["mogamulizumab","brentuximab-vedotin","allogeneic-hsct"],"guideline":{"nccn":"Category 1 (mogamulizumab, brentuximab)","version":"NCCN Guidelines: Primary Cutaneous Lymphomas"}},{"setting":"Extranodal NK/T-cell","approach":"Asparaginase-based chemotherapy (P-GemOx, SMILE) with involved-site radiotherapy for localised disease; PD-1 inhibitors at relapse.","refs":["pembrolizumab","imrt-igrt"]},{"setting":"Peripheral T-cell lymphoma: the questions that decide the regimen","approach":"Four things to establish before treatment. Which entity: ALK-positive anaplastic large cell lymphoma does much better than every other nodal T-cell lymphoma and is curable with chemotherapy alone in most patients; ALK-negative anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma not otherwise specified and the enteropathy-associated forms do considerably worse. CD30 expression by immunohistochemistry, because it decides whether brentuximab vedotin is added to first-line chemotherapy. Whether the disease is nodal, extranodal (nasal NK/T-cell), leukaemic (adult T-cell leukaemia/lymphoma, T-cell prolymphocytic leukaemia) or cutaneous, because those four groups have entirely different treatments. HTLV-1 serology where the patient comes from or has family from Japan, the Caribbean, west Africa, Iran or parts of South America, because adult T-cell leukaemia/lymphoma is treated differently from everything else.\n\nA breast implant-associated anaplastic large cell lymphoma presenting as a late seroma around an implant is treated primarily by complete surgical removal of the implant and capsule, and most patients need nothing else. That is a different disease from systemic anaplastic large cell lymphoma despite the shared name.","refs":["lymphoma-type","lymphoma-tx-regimen-alphabet","brentuximab-vedotin","fdg-pet","lugano-classification"],"guideline":{"version":"NCCN T-Cell Lymphomas; ESMO; WHO fifth edition","url":"https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq"}},{"setting":"First-line nodal peripheral T-cell lymphoma, CD30-positive: brentuximab vedotin with CHP","approach":"ECHELON-2 randomised 452 patients with untreated CD30-positive peripheral T-cell lymphoma to brentuximab vedotin with cyclophosphamide, doxorubicin and prednisone (A+CHP) or to CHOP. Median progression-free survival by blinded independent review was 48.2 against 20.8 months (hazard ratio 0.71), with improved overall survival, and toxicity was comparable: febrile neutropenia 18 against 15 per cent and peripheral neuropathy 52 against 55 per cent. It is the only positive randomised first-line trial in this family in twenty years and it changed the standard.\n\nThree-quarters of the trial population had systemic anaplastic large cell lymphoma, so the benefit is best established there and is extrapolated to other CD30-positive entities. Six cycles are given, with G-CSF support. Vincristine is omitted because brentuximab vedotin is itself a tubulin-directed agent and giving both causes unacceptable neuropathy.","refs":["echelon-2","brentuximab-vedotin","cyclophosphamide","doxorubicin","prednisone","g-csf-growth-factors","lymphoma-tx-regimen-alphabet","paper-horwitz-lancet"],"guideline":{"nccn":"Category 1 (A+CHP, CD30-positive)","version":"NCCN T-Cell Lymphomas; ESMO; ECHELON-2","url":"https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq"}},{"setting":"First-line nodal peripheral T-cell lymphoma, CD30-negative: CHOP, CHOEP and an honest account of the evidence","approach":"CHOP for six cycles is the default, and it is a default rather than a demonstrated best. No randomised trial has shown any regimen superior to CHOP in CD30-negative nodal peripheral T-cell lymphoma, and roughly half of patients are not cured by it.\n\nAdding etoposide (CHOEP) is standard in much of Europe for patients under 60 with a normal LDH, on the basis of a retrospective analysis of the German High-Grade Non-Hodgkin Lymphoma Study Group trials in which that subgroup had better event-free survival; the analysis was not randomised and not confined to T-cell lymphoma, so the practice rests on an observation rather than a trial. Adding romidepsin to CHOP was tested properly in the Ro-CHOP trial and failed, which is why the United States withdrew romidepsin's peripheral T-cell lymphoma indication.\n\nAngioimmunoblastic T-cell lymphoma is the entity in which the epigenetic drugs look most promising, because it is driven by mutations in TET2, DNMT3A, IDH2 and RHOA; azacitidine-containing combinations and histone deacetylase inhibitors are being tested and are not yet standard. Enteropathy-associated T-cell lymphoma is treated with intensive regimens and early nutritional support, because it presents with perforation or obstruction in a malnourished patient with coeliac disease.\n\nEntering a trial is a reasonable first choice rather than a last resort in this group.","refs":["r-chop","cyclophosphamide","doxorubicin","vincristine","prednisone","etoposide","romidepsin","lymphoma-tx-regimen-alphabet","lymphoma-tx-failed-and-negative"],"guideline":{"version":"NCCN T-Cell Lymphomas; ESMO; no randomised evidence for CHOEP over CHOP","url":"https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq"}},{"setting":"Autologous transplant consolidation in first remission","approach":"Consolidating a first complete or partial remission with high-dose therapy and an autologous stem cell transplant is standard practice in Europe and common in the United States for nodal peripheral T-cell lymphomas other than ALK-positive anaplastic large cell lymphoma, which does well enough without it. The evidence is a prospective single-arm Nordic study and a series of registry comparisons; there has never been a randomised trial, and the registry comparisons are subject to the obvious bias that only patients who respond well enough and stay fit enough reach transplant.\n\nSo the row is written as it is: this is the convention, it is reasonable, and a patient is entitled to be told that its benefit has not been demonstrated against continuing observation. Stem cells are collected after two to four cycles, before the marrow is exhausted. Allogeneic transplant is reserved for relapsed disease and for hepatosplenic T-cell lymphoma, where it is the only treatment that produces long remissions.","refs":["autologous-stem-cell-transplant","allogeneic-hsct","lymphoma-tx-transplant-role","carmustine","etoposide","cytarabine","melphalan"],"guideline":{"version":"NCCN T-Cell Lymphomas; ESMO; no randomised evidence","url":"https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq"}},{"setting":"Relapsed and refractory peripheral T-cell lymphoma","approach":"Response rates to every available single agent sit between about 25 and 35 per cent, and remissions are usually short, so the question at relapse is whether the patient can be taken to an allogeneic transplant or a trial.\n\nApproved single agents in the United States: pralatrexate, an antifolate, approved in 2009 on a response rate of about 29 per cent; belinostat, a histone deacetylase inhibitor, approved in 2014 on about 26 per cent, usable when platelets are low; romidepsin, approved in 2011 and withdrawn from this indication after the confirmatory Ro-CHOP trial failed. Brentuximab vedotin is highly active in relapsed systemic anaplastic large cell lymphoma, where response rates are far higher than in other entities; its first-line United States approval with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell lymphoma and other CD30-expressing peripheral T-cell lymphomas came on 16 November 2018. Availability differs sharply between countries: pralatrexate and belinostat are not routinely commissioned in England.\n\nOther options are gemcitabine-based chemotherapy (GemOx, GDP), which is widely used in the United Kingdom and has no randomised support, bendamustine, alemtuzumab in selected cases, and a clinical trial. Allogeneic transplant is the only treatment with curative potential at this point and is offered to fit patients who achieve a response. Valemetostat, an EZH1/EZH2 inhibitor, is approved in Japan for relapsed adult T-cell leukaemia/lymphoma and peripheral T-cell lymphoma and is in trials elsewhere; the corpus does not yet hold a record for it and this page does not quote a figure for it.","refs":["pralatrexate","belinostat","romidepsin","brentuximab-vedotin","gemcitabine","oxaliplatin","bendamustine","alemtuzumab","allogeneic-hsct","lymphoma-tx-transplant-role"],"guideline":{"version":"NCCN T-Cell Lymphomas; ESMO","url":"https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq"}}],"stateOfArt":["Brentuximab-CHP is the only regimen ever to improve survival over CHOP in PTCL, and only for CD30-positive disease.","Molecular subtyping (TFH, DUSP22, TP63) now guides prognosis and trial design, though not yet routine therapy.","Mogamulizumab and brentuximab give durable disease control in advanced cutaneous T-cell lymphoma.","Epigenetic therapy (azacitidine, HDAC inhibitors) is most active in TFH lymphomas with TET2/DNMT3A mutations.","The T-cell lymphomas are where the antigen problem is hardest, because the tumour and the effector are the same kind of cell. CD52 is on B cells, T cells, monocytes and dendritic cells, so alemtuzumab leaves CD4 counts low for a year; CCR4 is on regulatory T cells as well as on the tumour; and a CD3-engaging bispecific cannot be used the way it is in B-cell disease.","JAK-STAT is the recurring signalling lesion. Activating STAT3 and STAT5B mutations were found across 51 NK/T-cell lymphomas and 43 gamma-delta T-cell lymphomas, with STAT5B N642H particularly frequent in the gamma-delta group; the substitution raises the affinity of the phosphotyrosine for the mutant histidine so the active form persists.","HTLV-1 defines adult T-cell leukaemia/lymphoma, and the genomics show it is not simply a viral disease: across 426 cases, the acquired alterations overlapped significantly with the proteins the viral Tax protein binds, concentrating in T-cell receptor and NF-kB signalling, trafficking and immune surveillance, with activating CCR4 mutations among them."],"history":[{"year":1975,"title":"Mycosis fungoides staging (TNMB)","refs":[]},{"year":1994,"title":"ALK fusion in anaplastic large-cell lymphoma","note":"NPM-ALK identified by Morris et al.; ALK-positive ALCL becomes the good-prognosis PTCL.","refs":["alk"]},{"year":2009,"title":"Pralatrexate and romidepsin approved","note":"First drugs specifically for relapsed PTCL.","refs":["pralatrexate","romidepsin"]},{"year":2011,"title":"Brentuximab vedotin approved for ALCL","refs":["brentuximab-vedotin"]},{"year":2014,"title":"Belinostat approved","refs":["belinostat"]},{"year":2017,"title":"ALCANZA: brentuximab in CD30+ CTCL","refs":["brentuximab-vedotin"]},{"year":2018,"title":"ECHELON-2 and mogamulizumab","note":"Brentuximab-CHP improves OS over CHOP; mogamulizumab approved for MF/Sézary (MAVORIC).","refs":["brentuximab-vedotin","mogamulizumab"]},{"year":2021,"title":"Romidepsin US PTCL indication withdrawn","note":"Confirmatory Ro-CHOP trial negative.","refs":["romidepsin"]}],"pipeline":["brentuximab-vedotin","azacitidine","allogeneic-hsct","soquelitinib","azd3470","dr-01"],"openProblems":["Five-year survival under 40% for PTCL-NOS with no new first-line regimen for non-CD30 disease.","Randomised evidence for transplant consolidation is lacking.","T-cell CAR-T faces fratricide and T-cell aplasia.","Most subtypes too rare for conventional phase 3 trials.","Almost nothing given in peripheral T-cell lymphoma rests on a randomised trial. CHOP is the default without ever having been shown superior to anything; CHOEP rests on a retrospective subgroup; autologous transplant consolidation in first remission rests on a single-arm study and registry comparisons that select for the patients who were going to do well.","Adding romidepsin to CHOP failed in Ro-CHOP and the indication was withdrawn, leaving the CD30-negative nodal T-cell lymphomas with no advance since CHOP itself.","Extranodal NK/T-cell lymphoma and adult T-cell leukaemia/lymphoma are common in east Asia, the Caribbean and west Africa and rare in the countries that run most trials, so their evidence base is thin in exactly the places where patients are treated outside those regions.","Valemetostat is approved in Japan for relapsed adult T-cell leukaemia/lymphoma and peripheral T-cell lymphoma and has no record in this corpus and no approval in the United Kingdom or the United States at the time of writing, which is a gap rather than a judgement."],"parent":"non-hodgkin-lymphoma"},"route":"/cancers/peripheral-t-cell-lymphoma/","neighbours":{"cancer":[{"id":"adult-t-cell-leukaemia-lymphoma","kind":"cancer","name":"Adult T-cell leukaemia/lymphoma","route":"/cancers/adult-t-cell-leukaemia-lymphoma/"},{"id":"alk-negative-anaplastic-large-cell-lymphoma","kind":"cancer","name":"ALK-negative anaplastic large cell lymphoma","route":"/cancers/alk-negative-anaplastic-large-cell-lymphoma/"},{"id":"alk-positive-anaplastic-large-cell-lymphoma","kind":"cancer","name":"ALK-positive anaplastic large cell lymphoma","route":"/cancers/alk-positive-anaplastic-large-cell-lymphoma/"},{"id":"breast-implant-associated-alcl","kind":"cancer","name":"Breast implant-associated anaplastic large cell lymphoma","route":"/cancers/breast-implant-associated-alcl/"},{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"enteropathy-associated-t-cell-lymphoma","kind":"cancer","name":"Enteropathy-associated T-cell lymphoma","route":"/cancers/enteropathy-associated-t-cell-lymphoma/"},{"id":"extranodal-nk-t-cell-lymphoma","kind":"cancer","name":"Extranodal NK/T-cell lymphoma","route":"/cancers/extranodal-nk-t-cell-lymphoma/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"hepatosplenic-t-cell-lymphoma","kind":"cancer","name":"Hepatosplenic T-cell lymphoma","route":"/cancers/hepatosplenic-t-cell-lymphoma/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"monomorphic-epitheliotropic-intestinal-t-cell-lymphoma","kind":"cancer","name":"Monomorphic epitheliotropic intestinal T-cell lymphoma","route":"/cancers/monomorphic-epitheliotropic-intestinal-t-cell-lymphoma/"},{"id":"mycosis-fungoides","kind":"cancer","name":"Mycosis fungoides","route":"/cancers/mycosis-fungoides/"},{"id":"angioimmunoblastic-t-cell-lymphoma","kind":"cancer","name":"Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)","route":"/cancers/angioimmunoblastic-t-cell-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"sezary-syndrome","kind":"cancer","name":"Sezary syndrome","route":"/cancers/sezary-syndrome/"}],"biomarker":[{"id":"cd30-expression","kind":"biomarker","name":"CD30 expression (CD30-positive)","route":"/biomarkers/cd30-expression/"},{"id":"cd38-expression","kind":"biomarker","name":"CD38 expression","route":"/biomarkers/cd38-expression/"},{"id":"ig-tcr-clonality","kind":"biomarker","name":"Immunoglobulin and T-cell receptor clonality","route":"/biomarkers/ig-tcr-clonality/"},{"id":"rhoa-g17v","kind":"biomarker","name":"RHOA G17V","route":"/biomarkers/rhoa-g17v/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}],"idea":[{"id":"lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas","kind":"idea","name":"Randomised evidence for the T-cell lymphomas, including the ones that are not in Europe or North America","route":"/ideas/lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas/"},{"id":"lymphoma-ev-the-drugs-that-cure-and-the-places-without-them","kind":"idea","name":"The drugs that cure lymphoma, and the places that do not have them","route":"/ideas/lymphoma-ev-the-drugs-that-cure-and-the-places-without-them/"}],"technology":[{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/"},{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"cbt-fatigue-distress","kind":"technology","name":"Cognitive behavioural therapy for fatigue and distress","route":"/technologies/cbt-fatigue-distress/"},{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/"},{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"},{"id":"exercise-during-chemotherapy","kind":"technology","name":"Exercise during chemotherapy and radiotherapy","route":"/technologies/exercise-during-chemotherapy/"},{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/"},{"id":"financial-navigation","kind":"technology","name":"Financial toxicity and financial navigation","route":"/technologies/financial-navigation/"},{"id":"g-csf-growth-factors","kind":"technology","name":"Growth factors: G-CSF and febrile neutropenia prevention","route":"/technologies/g-csf-growth-factors/"},{"id":"histopathology-ihc","kind":"technology","name":"Histopathology & immunohistochemistry","route":"/technologies/histopathology-ihc/"},{"id":"clonality-testing","kind":"technology","name":"Immunoglobulin and T-cell receptor clonality testing","route":"/technologies/clonality-testing/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"multidisciplinary-tumour-board","kind":"technology","name":"Multidisciplinary tumour boards","route":"/technologies/multidisciplinary-tumour-board/"},{"id":"flow-cytometry-mrd","kind":"technology","name":"Multiparameter flow cytometry MRD","route":"/technologies/flow-cytometry-mrd/"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/"},{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/"},{"id":"peer-support-groups","kind":"technology","name":"Peer support and support groups","route":"/technologies/peer-support-groups/"},{"id":"prehabilitation","kind":"technology","name":"Prehabilitation before cancer surgery","route":"/technologies/prehabilitation/"},{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/"},{"id":"total-skin-electron-therapy","kind":"technology","name":"Total skin electron beam therapy","route":"/technologies/total-skin-electron-therapy/"}],"target":[{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/"},{"id":"card11","kind":"target","name":"CARD11","route":"/targets/card11/"},{"id":"ccr4","kind":"target","name":"CCR4","route":"/targets/ccr4/"},{"id":"cd25","kind":"target","name":"CD25 (IL-2 receptor alpha)","route":"/targets/cd25/"},{"id":"cd30","kind":"target","name":"CD30","route":"/targets/cd30/"},{"id":"cd38","kind":"target","name":"CD38","route":"/targets/cd38/"},{"id":"cd52","kind":"target","name":"CD52","route":"/targets/cd52/"},{"id":"cd7","kind":"target","name":"CD7","route":"/targets/cd7/"},{"id":"cd80","kind":"target","name":"CD80 (B7-1)","route":"/targets/cd80/"},{"id":"dnmt3a","kind":"target","name":"DNA methyltransferase 3A (DNMT3A)","route":"/targets/dnmt3a/"},{"id":"fyn","kind":"target","name":"FYN","route":"/targets/fyn/"},{"id":"hdac","kind":"target","name":"Histone deacetylases (HDAC)","route":"/targets/hdac/"},{"id":"irf4","kind":"target","name":"IRF4","route":"/targets/irf4/"},{"id":"jak1","kind":"target","name":"JAK1","route":"/targets/jak1/"},{"id":"jak3","kind":"target","name":"JAK3","route":"/targets/jak3/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"plcg1","kind":"target","name":"PLCG1","route":"/targets/plcg1/"},{"id":"rhoa","kind":"target","name":"RHOA","route":"/targets/rhoa/"},{"id":"stat3","kind":"target","name":"STAT3","route":"/targets/stat3/"},{"id":"stat5","kind":"target","name":"STAT5 (STAT5A, STAT5B)","route":"/targets/stat5/"},{"id":"tet2","kind":"target","name":"TET2","route":"/targets/tet2/"},{"id":"vav1","kind":"target","name":"VAV1","route":"/targets/vav1/"}],"drug":[{"id":"alemtuzumab","kind":"drug","name":"Alemtuzumab","route":"/drugs/alemtuzumab/"},{"id":"asparaginase","kind":"drug","name":"Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)","route":"/drugs/asparaginase/"},{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"azd3470","kind":"drug","name":"AZD3470","route":"/drugs/azd3470/"},{"id":"belinostat","kind":"drug","name":"Belinostat","route":"/drugs/belinostat/"},{"id":"bendamustine","kind":"drug","name":"Bendamustine","route":"/drugs/bendamustine/"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"},{"id":"carmustine","kind":"drug","name":"Carmustine","route":"/drugs/carmustine/"},{"id":"crizotinib","kind":"drug","name":"Crizotinib","route":"/drugs/crizotinib/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"cytarabine","kind":"drug","name":"Cytarabine","route":"/drugs/cytarabine/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"dr-01","kind":"drug","name":"DR-01","route":"/drugs/dr-01/"},{"id":"duvelisib","kind":"drug","name":"Duvelisib","route":"/drugs/duvelisib/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"golidocitinib","kind":"drug","name":"Golidocitinib","route":"/drugs/golidocitinib/"},{"id":"interferon-alfa","kind":"drug","name":"Interferon alfa-2a/2b","route":"/drugs/interferon-alfa/"},{"id":"melphalan","kind":"drug","name":"Melphalan (including hepatic delivery system)","route":"/drugs/melphalan/"},{"id":"methoxsalen-ecp","kind":"drug","name":"Methoxsalen (extracorporeal photopheresis)","route":"/drugs/methoxsalen-ecp/"},{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","route":"/drugs/mogamulizumab/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pralatrexate","kind":"drug","name":"Pralatrexate","route":"/drugs/pralatrexate/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"},{"id":"romidepsin","kind":"drug","name":"Romidepsin","route":"/drugs/romidepsin/"},{"id":"soquelitinib","kind":"drug","name":"Soquelitinib","route":"/drugs/soquelitinib/"},{"id":"sugemalimab","kind":"drug","name":"Sugemalimab","route":"/drugs/sugemalimab/"},{"id":"tucidinostat","kind":"drug","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/"},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/"}],"company":[{"id":"acrotech-biopharma","kind":"company","name":"Acrotech Biopharma","route":"/companies/acrotech-biopharma/"},{"id":"bioinvent-international","kind":"company","name":"BioInvent International","route":"/companies/bioinvent-international/"},{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"},{"id":"evopoint-biosciences","kind":"company","name":"Evopoint Biosciences","route":"/companies/evopoint-biosciences/"},{"id":"haihe-biopharma","kind":"company","name":"Haihe Biopharma","route":"/companies/haihe-biopharma/"},{"id":"huyabio","kind":"company","name":"HUYABIO International","route":"/companies/huyabio/"},{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","route":"/companies/immuneoncia-therapeutics/"},{"id":"mundipharma","kind":"company","name":"Mundipharma","route":"/companies/mundipharma/"},{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"},{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/"}],"pathway":[{"id":"epigenetic-reprogramming","kind":"pathway","name":"Epigenetic reprogramming","route":"/pathways/epigenetic-reprogramming/"},{"id":"inflammation-nfkb","kind":"pathway","name":"Inflammation & NF-κB","route":"/pathways/inflammation-nfkb/"},{"id":"jak-stat","kind":"pathway","name":"JAK-STAT signalling","route":"/pathways/jak-stat/"},{"id":"oncogenic-viruses","kind":"pathway","name":"Oncogenic viruses","route":"/pathways/oncogenic-viruses/"}],"term":[{"id":"lymphoma-decision-trial","kind":"term","name":"A clinical trial or standard treatment in lymphoma","route":"/terms/lymphoma-decision-trial/"},{"id":"lymphoma-b-versus-t-cell","kind":"term","name":"B-cell, T-cell and NK-cell lymphoma","route":"/terms/lymphoma-b-versus-t-cell/"},{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/"},{"id":"central-venous-access","kind":"term","name":"Central venous access (port, PICC line)","route":"/terms/central-venous-access/"},{"id":"lymphoma-bio-ebv-latency","kind":"term","name":"Epstein-Barr virus latency programmes, and why they decide which lymphoma","route":"/terms/lymphoma-bio-ebv-latency/"},{"id":"lymphoma-living-fatigue","kind":"term","name":"Fatigue after lymphoma treatment, and why it is a symptom to report","route":"/terms/lymphoma-living-fatigue/"},{"id":"febrile-neutropenia","kind":"term","name":"Febrile neutropenia","route":"/terms/febrile-neutropenia/"},{"id":"lymphoma-decision-fertility-timing","kind":"term","name":"Fertility preservation before lymphoma treatment: a decision with a deadline in days","route":"/terms/lymphoma-decision-fertility-timing/"},{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/"},{"id":"lymphoma-living-returning-to-work","kind":"term","name":"Going back to work after lymphoma, and the money in the meantime","route":"/terms/lymphoma-living-returning-to-work/"},{"id":"histologic-transformation","kind":"term","name":"Histologic transformation","route":"/terms/histologic-transformation/"},{"id":"lymphoma-htlv-1","kind":"term","name":"HTLV-1 (human T-lymphotropic virus type 1)","route":"/terms/lymphoma-htlv-1/"},{"id":"lymphoma-bio-htlv1","kind":"term","name":"HTLV-1, Tax and HBZ in adult T-cell leukaemia/lymphoma","route":"/terms/lymphoma-bio-htlv1/"},{"id":"hypogammaglobulinaemia","kind":"term","name":"Hypogammaglobulinaemia and infection risk after B-cell therapies","route":"/terms/hypogammaglobulinaemia/"},{"id":"lymphoma-indolent-versus-aggressive","kind":"term","name":"Indolent and aggressive lymphoma","route":"/terms/lymphoma-indolent-versus-aggressive/"},{"id":"lymphoma-tx-pjp-and-infection-prophylaxis","kind":"term","name":"Infection prophylaxis in lymphoma: PJP, herpes, fungal risk and vaccination","route":"/terms/lymphoma-tx-pjp-and-infection-prophylaxis/"},{"id":"late-effects","kind":"term","name":"Late effects and survivorship toxicity","route":"/terms/late-effects/"},{"id":"lugano-classification","kind":"term","name":"Lugano classification / Ann Arbor staging","route":"/terms/lugano-classification/"},{"id":"lymphoma-type","kind":"term","name":"Lymphoma (tissue type)","route":"/terms/lymphoma-type/"},{"id":"lymphoma-tx-failed-and-negative","kind":"term","name":"Lymphoma treatments that did not work: the negative trials worth knowing","route":"/terms/lymphoma-tx-failed-and-negative/"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/"},{"id":"performance-status","kind":"term","name":"Performance status (ECOG, Karnofsky)","route":"/terms/performance-status/"},{"id":"plasma-ebv-dna","kind":"term","name":"Plasma EBV DNA","route":"/terms/plasma-ebv-dna/"},{"id":"lymphoma-pit-score","kind":"term","name":"Prognostic Index for T-cell lymphoma (PIT)","route":"/terms/lymphoma-pit-score/"},{"id":"quality-of-life","kind":"term","name":"Quality of life","route":"/terms/quality-of-life/"},{"id":"r-chop","kind":"term","name":"R-CHOP (lymphoma chemoimmunotherapy)","route":"/terms/r-chop/"},{"id":"lymphoma-tx-radiotherapy","kind":"term","name":"Radiotherapy in lymphoma: involved-site fields, 24 Gy, 4 Gy and total skin electron therapy","route":"/terms/lymphoma-tx-radiotherapy/"},{"id":"lymphoma-tx-transplant-role","kind":"term","name":"Stem cell transplant in lymphoma: what it is still for","route":"/terms/lymphoma-tx-transplant-role/"},{"id":"lymphoma-tx-regimen-alphabet","kind":"term","name":"The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest","route":"/terms/lymphoma-tx-regimen-alphabet/"},{"id":"lymphoma-living-scanxiety-and-surveillance","kind":"term","name":"The surveillance schedule, and the evidence that routine scans do not find relapse first","route":"/terms/lymphoma-living-scanxiety-and-surveillance/"},{"id":"lymphoma-classification-2022","kind":"term","name":"The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC)","route":"/terms/lymphoma-classification-2022/"},{"id":"tumor-lysis-syndrome","kind":"term","name":"Tumour lysis syndrome (TLS)","route":"/terms/tumor-lysis-syndrome/"},{"id":"lymphoma-living-vaccinations","kind":"term","name":"Vaccinations around lymphoma treatment: the ones to have first, and the ones not to have at all","route":"/terms/lymphoma-living-vaccinations/"},{"id":"lymphoma-bio-lineage-antigen-cost","kind":"term","name":"What it costs to aim at a lineage antigen","route":"/terms/lymphoma-bio-lineage-antigen-cost/"},{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/"}],"trial":[{"id":"nct05463263","kind":"trial","name":"A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas","route":"/trials/nct05463263/"},{"id":"nct07234162","kind":"trial","name":"A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)","route":"/trials/nct07234162/"},{"id":"nct06485219","kind":"trial","name":"A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","route":"/trials/nct06485219/"},{"id":"nct06776952","kind":"trial","name":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","route":"/trials/nct06776952/"},{"id":"nct05673785","kind":"trial","name":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","route":"/trials/nct05673785/"},{"id":"nct05475925","kind":"trial","name":"A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas","route":"/trials/nct05475925/"},{"id":"nct05934513","kind":"trial","name":"A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","route":"/trials/nct05934513/"},{"id":"nct05627856","kind":"trial","name":"A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL","route":"/trials/nct05627856/"},{"id":"nct04414163","kind":"trial","name":"A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type","route":"/trials/nct04414163/"},{"id":"nct06035497","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)","route":"/trials/nct06035497/"},{"id":"nct07523555","kind":"trial","name":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","route":"/trials/nct07523555/"},{"id":"alcanza","kind":"trial","name":"ALCANZA","route":"/trials/alcanza/"},{"id":"nct07496229","kind":"trial","name":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","route":"/trials/nct07496229/"},{"id":"nct05833724","kind":"trial","name":"Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)","route":"/trials/nct05833724/"},{"id":"nct04668690","kind":"trial","name":"Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL","route":"/trials/nct04668690/"},{"id":"nct07730515","kind":"trial","name":"Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma","route":"/trials/nct07730515/"},{"id":"nct06470451","kind":"trial","name":"Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL","route":"/trials/nct06470451/"},{"id":"echelon-2","kind":"trial","name":"ECHELON-2","route":"/trials/echelon-2/"},{"id":"nct04390737","kind":"trial","name":"Evaluate the Safety and Clinical Activity of HH2853","route":"/trials/nct04390737/"},{"id":"nct04930653","kind":"trial","name":"Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma","route":"/trials/nct04930653/"},{"id":"nct06149247","kind":"trial","name":"HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL","route":"/trials/nct06149247/"},{"id":"jcog9801","kind":"trial","name":"JCOG9801","route":"/trials/jcog9801/"},{"id":"mavoric","kind":"trial","name":"MAVORIC","route":"/trials/mavoric/"},{"id":"nct06534060","kind":"trial","name":"MB-105 in Patients With CD5 Positive T-cell Lymphoma","route":"/trials/nct06534060/"},{"id":"nct01686594","kind":"trial","name":"PUVA Maintenance Therapy in Mycosis Fungoides","route":"/trials/nct01686594/"},{"id":"nct04747236","kind":"trial","name":"Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL","route":"/trials/nct04747236/"},{"id":"nct02953301","kind":"trial","name":"Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)","route":"/trials/nct02953301/"},{"id":"smile-enktl","kind":"trial","name":"SMILE","route":"/trials/smile-enktl/"},{"id":"nct06561048","kind":"trial","name":"Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma","route":"/trials/nct06561048/"},{"id":"nct06909877","kind":"trial","name":"Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma","route":"/trials/nct06909877/"},{"id":"nct06072131","kind":"trial","name":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","route":"/trials/nct06072131/"},{"id":"nct06947967","kind":"trial","name":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","route":"/trials/nct06947967/"},{"id":"nct04703192","kind":"trial","name":"Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)","route":"/trials/nct04703192/"}],"paper":[{"id":"paper-hinuma-adult-t-cell-leukaemia-antigen-pnas-1981","kind":"paper","name":"Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera","route":"/key-papers/paper-hinuma-adult-t-cell-leukaemia-antigen-pnas-1981/"},{"id":"paper-horwitz-lancet","kind":"paper","name":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","route":"/key-papers/paper-horwitz-lancet/"},{"id":"paper-poiesz-htlv-retrovirus-cutaneous-t-cell-lymphoma-pnas-1980","kind":"paper","name":"Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma","route":"/key-papers/paper-poiesz-htlv-retrovirus-cutaneous-t-cell-lymphoma-pnas-1980/"},{"id":"paper-smile-chemotherapy-nk-t-cell-lymphoma-jco-2011","kind":"paper","name":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","route":"/key-papers/paper-smile-chemotherapy-nk-t-cell-lymphoma-jco-2011/"},{"id":"paper-jcog9801-vcap-amp-vecp-adult-t-cell-leukaemia-jco-2007","kind":"paper","name":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","route":"/key-papers/paper-jcog9801-vcap-amp-vecp-adult-t-cell-leukaemia-jco-2007/"}],"institution":[{"id":"anthony-nolan","kind":"institution","name":"Anthony Nolan","route":"/institutions/anthony-nolan/"},{"id":"blood-cancer-uk","kind":"institution","name":"Blood Cancer UK","route":"/institutions/blood-cancer-uk/"},{"id":"lymphoma-action","kind":"institution","name":"Lymphoma Action","route":"/institutions/lymphoma-action/"}],"person":[{"id":"miles-prince","kind":"person","name":"H. Miles Prince","route":"/people/miles-prince/"},{"id":"lim-soon-thye","kind":"person","name":"Lim Soon Thye","route":"/people/lim-soon-thye/"},{"id":"steven-horwitz","kind":"person","name":"Steven M. Horwitz","route":"/people/steven-horwitz/"},{"id":"youn-kim","kind":"person","name":"Youn H. Kim","route":"/people/youn-kim/"}],"collection":[{"id":"lymphoma-research-foundation","kind":"collection","name":"Lymphoma Research Foundation (LRF)","route":"/collections/lymphoma-research-foundation/"}]}}